{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:DOC-TC0SV6ZS/244c0261-e6fc-4cad-b086-e3a92675bf2e/HTML","dcterms:extent":"10 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:DOC-TC0SV6ZS/1124b44d-52a9-41ae-815f-85b38ce21669/PDF","dcterms:extent":"81 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:DOC-TC0SV6ZS/6c5551d4-ee91-4da4-8ac5-e72321794a09/TEXT","dcterms:extent":"10 KB"}],"edm:TimeSpan":{"@rdf:about":"1929-2026","edm:begin":{"@xml:lang":"en","#text":"1929"},"edm:end":{"@xml:lang":"en","#text":"2026"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:DOC-TC0SV6ZS","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/urn:nbn:si:spr-a30mfzkp"},{"@xml:lang":"sl","#text":"Zdravniški vestnik"}],"dcterms:issued":"2005","dc:creator":["Avancini, Nives","Godina-Kariž, Stanka","Kariž, Stojan"],"dc:format":[{"@xml:lang":"sl","#text":"številka:10"},{"@xml:lang":"sl","#text":"letnik:74"},{"@xml:lang":"sl","#text":"str. 655-656"}],"dc:identifier":["ISSN:1318-0347","COBISSID:20411865","URN:URN:NBN:SI:doc-TC0SV6ZS"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko zdravniško društvo"},"dc:subject":[{"@xml:lang":"en","#text":"Adverse Effects"},{"@xml:lang":"en","#text":"Drug Therapy"},{"@xml:lang":"en","#text":"Fundus Oculi"},{"@xml:lang":"en","#text":"Hepatitis C"},{"@xml:lang":"sl","#text":"interferon"},{"@xml:lang":"en","#text":"Interferon-alfa"},{"@xml:lang":"en","#text":"Interferon-Alpha"},{"@xml:lang":"sl","#text":"izguba vida"},{"@xml:lang":"en","#text":"Middle Age"},{"@xml:lang":"sl","#text":"Očesno ozadje"},{"@xml:lang":"sl","#text":"oftalmologija"},{"@xml:lang":"en","#text":"Optic Neuropathy, Ischemic"},{"@xml:lang":"sl","#text":"Optična nevropatija ishemična"},{"@xml:lang":"sl","#text":"Srednja leta"},{"@xml:lang":"en","#text":"Therapeutic Use"},{"@xml:lang":"en","#text":"therapy"},{"@xml:lang":"sl","#text":"vid"},{"@xml:lang":"sl","#text":"zdravljenje"}],"dcterms:temporal":{"@rdf:resource":"1929-2026"},"dc:title":{"@xml:lang":"sl","#text":"Anteriorna ishemična optična nevropatija kot posledica zdravljenja z interferonom alfa| Anterior ischemic optic neuropathy secondary to interferon alpha|"},"dc:description":[{"@xml:lang":"sl","#text":"Background. Anterior ischemic optic neuropathy rarely occurs with interferon alpha therapy. The mechanism by which interferon induces anterior ischemic optic neuropathy is unknown. Methods. A 62-year-old man presented with complaints of sudden severe loss of vision in the left eye. He has been receiving interferon alpha and ribavirin for chronic infection with hepatitis C virus. Vision loss occurred 6 months after the beginning of treatment. Afterwe ruled out other possible etiologies, a diagnosis of anterior ischemic optic neuropathy due to interferon therapy was made and the drug was discontinued. A follow up 3 weeks later showed an improvement of visual acuityand resolution of scotoma, disc hemorrhage and edema. Conclusions. The resolution of anterior ischemic optic neuropathy after discontinuation of interferon suggested a casual relation, though the pathophysiologic mechanism remains unknown. An ophthalmologic examination should be performed in patientswith risk factors of visual loss before and regularly during interferon treatment"},{"@xml:lang":"sl","#text":"Izhodišča. Anteriorna ishemična optična nevropatija je redek zaplet zdravljenja z interferonom alfa. Mehanizem nastanka še vedno ni znan. Metode. Predstavljamo primer 62-letnega moškega z nenadno hudo izgubo vida na levem očesu. Zaradi okužbe z virusom hepatitisa C je prejemal interferon alfa z ribavirinom. Upad vida je nastopil 6 mesecev po pričetku zdravljenja. Ob izključitvi drugih dejavnikov smo menili, da je anteriorna ishemična nevropatija posledica zdravljenja z interferonom in prenehali z zdravljenjem. Po treh tednih smo spremljali izboljšanje vida in nazadovanje skotoma peripapilarnih krvavitev in edema optičnega živca. Zaključki. Izboljšanje anteriorne optične nevropatije po prekinitvi zdravljenja z interferonom kaže na vzročno povezavo, čeprav patofiziološki mehanizem nastanka še vedno ni znan. Bolnike z dejavniki tveganja za izgubo vida mora pred uvedbo in med zdravljenjem z inerferonom redno spremljati oftalmolog"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:DOC-TC0SV6ZS","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:DOC-TC0SV6ZS"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:DOC-TC0SV6ZS/1124b44d-52a9-41ae-815f-85b38ce21669/PDF"},"edm:rights":{"@rdf:resource":"http://creativecommons.org/licenses/by-nc/4.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko zdravniško društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:DOC-TC0SV6ZS/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:DOC-TC0SV6ZS"}}}}